Skip to content

Nuvalent, Inc. NUVL Retained Earnings

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$4.36B-24.4%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$2.48B-94.4%
Exelixis logo
ExelixisEXEL
-$215.79M-32.2%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$3.32B-70.3%
Incyte logo
IncyteINCY
$517.1M+157%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s retained earnings?
Nuvalent, Inc. (NUVL) reported retained earnings of -$1.08B in Q1 2026.
How has Nuvalent, Inc.'s retained earnings changed year-over-year?
Nuvalent, Inc.'s retained earnings decreased by 71.3% year-over-year, from -$631.63M to -$1.08B.
What is the long-term trend for Nuvalent, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s retained earnings has grown at a 98.1% compound annual growth rate (CAGR), from -$31.89M to -$972.43M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.